Jerusalem, 25 October, 2026 (TPS-IL) — Israel’s Health Ministry launched a groundbreaking national clinical trial using psychoactive substances to treat PTSD amid the ongoing mental health crisis following the October 7 massacre.
The unprecedented, large-scale study will treat hundreds of trauma survivors using medical-grade MDMA (the active ingredient in ecstasy) and psilocybin (magic mushrooms) in highly controlled therapeutic settings.
The Ministry aims to evaluate the safety and clinical efficacy of these controversial substances as fast-tracked therapeutic catalysts. Proponents highlight how MDMA and psilocybin can suppress neural fear pathways, allowing patients to process core trauma without psychological flooding.
While the FDA recently stalled commercial approvals over safety and trial-design concerns, Israel’s severe psychiatric backlog has prompted direct governmental intervention. This trial positions Israel as a global pioneer in psychedelic medicine, shifting controlled substances into heavily monitored, frontline clinical interventions for trauma recovery.
